Healthcare >> CEO Interviews >> December 18, 2000
TAYLOR J. CROUCH became President, Chief Executive Officer, and a member
of the Board of Directors of Variagenics, Inc., in April 1999. Under his
leadership, the company has grown from research-based start-up to a
public biotechnology company, positioned to lead in commercializing
pharmacogenomics technologies for drug and diagnostic applications.
Since Mr. Crouch joined Variagenics, the company has formed strategic
collaborations with contract research organizations and life science and
pharmaceutical companies, including Covance, Waters and Boehringer
Ingelheim. Also, during this time, Variagenics has raised approximately
$120 million, $81 million of which resulted from the company's
successful, July 2000 initial public offering. From 1991 to April 1999,
Mr. Crouch was Senior Vice President, Worldwide Marketing and Strategic
Development for PAREXEL International Corporation, where he established
strategic partnerships in all major pharmaceutical marketplaces. Prior
to joining PAREXEL, Mr. Crouch spent 10 years in the pharmaceutical and
device industries in new product development marketing at Schering-
Plough International, Pfizer International, and Johnson & Johnson's
Critikon division. Within the pharmaceutical industry, he has worked on
the development and launch of many leading products in the
cardiovascular, anti-infectives, dermatology, and allergy fields. Mr.
Crouch received his BS in Chemical Engineering from Princeton University
and his MBA in International Finance and Marketing from the University
of Chicago. Profile
Mr. Crouch: VARIAGENICS is a leader in pharmacogenomics. We were one of
the first companies to put this term on the books.
